| 000 | 01840 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250513083032.0 | ||
| 264 | 0 | _c19960119 | |
| 008 | 199601s 0 0 eng d | ||
| 022 | _a0269-9370 | ||
| 024 | 7 |
_a10.1097/00002030-199510000-00011 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKassim, S | |
| 245 | 0 | 0 |
_aTwo-year follow-up of persons with HIV-1- and HIV-2-associated pulmonary tuberculosis treated with short-course chemotherapy in West Africa. _h[electronic resource] |
| 260 |
_bAIDS (London, England) _cOct 1995 |
||
| 300 |
_a1185-91 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 |
_aAIDS-Related Opportunistic Infections _xcomplications |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAfrica, Western |
| 650 | 0 | 4 |
_aAntibiotics, Antitubercular _xtherapeutic use |
| 650 | 0 | 4 |
_aAntitubercular Agents _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHIV Seronegativity |
| 650 | 0 | 4 |
_aHIV Seropositivity _xcomplications |
| 650 | 0 | 4 | _aHIV-1 |
| 650 | 0 | 4 | _aHIV-2 |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoniazid _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPyrazinamide _xtherapeutic use |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 |
_aRifampin _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Failure |
| 650 | 0 | 4 |
_aTuberculosis, Pulmonary _xcomplications |
| 700 | 1 | _aSassan-Morokro, M | |
| 700 | 1 | _aAckah, A | |
| 700 | 1 | _aAbouya, L Y | |
| 700 | 1 | _aDigbeu, H | |
| 700 | 1 | _aYesso, G | |
| 700 | 1 | _aCoulibaly, I M | |
| 700 | 1 | _aCoulibaly, D | |
| 700 | 1 | _aWhitaker, P J | |
| 700 | 1 | _aDoorly, R | |
| 773 | 0 |
_tAIDS (London, England) _gvol. 9 _gno. 10 _gp. 1185-91 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00002030-199510000-00011 _zAvailable from publisher's website |
| 999 |
_c8518711 _d8518711 |
||